Skip to main content
. 2023 Apr 3;61(4):2200725. doi: 10.1183/13993003.00725-2022

FIGURE 1.

FIGURE 1

Improvement of forced expiratory volume in 1 s and sweat chloride concentration (SSC) after elexacaftor/tezacaftor/ivacaftor therapy. a) FEV1 % pred and b) SSC in F508del homozygous (n=14) and heterozygous (n=27) people with cystic fibrosis before (Pre) and after 1 (M1) and 6 (M6) months of therapy. Box plots with median and whiskers pointing to minimum and maximum values. One-way ANOVA with Tukey's multiple comparison test. *: p<0.05; **: p<0.01; ****: p<0.0001.